Allogene Therapeutics
Wei-Meng Zhao has extensive work experience in the field of product quality and research. Currently, they are serving as the Senior Director and Product Quality Leader at Allogene Therapeutics since May 2022. Prior to this, they were the Head of Quality Research and Quality Control at Gene Quantum from August 2021 to April 2022. Wei-Meng also worked at Genentech, where they held various positions including Principal Quality Product Leader, Senior Quality Product Leader, Senior Scientist, and QC Scientist from 2009 to 2021. Before joining Genentech, they were a Staff Scientist at Galaxy Biotech from 2007 to 2009. Wei-Meng's career began at Stanford University, where they worked as a Postdoctoral Fellow from September 2001 to December 2006.
Wei-Meng Zhao completed their Bachelor of Science degree in Biology at Tsinghua University from 1989 to 1994. Wei-Meng then pursued further education and obtained a Ph.D. in Biochemistry from the University of Notre Dame, completing their studies from 1995 to 2001. Later, from 2008 to 2010, Wei-Meng Zhao attended the University of California, Santa Cruz, where they earned a Certificate in Regulatory Affairs.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.